Oral Micronized Progesterone and Trazodone Interaction: Safety, Risks, and Clinical Guidance

Why This Interaction Matters

Oral micronized progesterone (brand name Prometrium) is prescribed to millions of menopausal and perimenopausal women for endometrial protection during estrogen therapy, and trazodone remains one of the most widely prescribed off-label sleep aids in the United States. Clinicians frequently encounter patients taking both. The interaction sits in the moderate-severity tier across major drug interaction databases, including Lexicomp, Clinical Pharmacology, and Micromedex, because it involves two mechanisms operating simultaneously: shared hepatic metabolism and additive central nervous system (CNS) depression.

Neither the FDA-approved Prometrium label nor the FDA-approved trazodone label lists the other drug as a specific contraindication. That absence does not mean the combination is risk-free. It means the interaction is manageable with proper clinical attention. A 2019 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that co-reported CNS depressant combinations involving trazodone were associated with a disproportionality signal for excessive sedation events (reporting odds ratio 2.1 to 95% CI 1.6 to 2.8) [1]. The practical question is not whether to avoid the pair but how to dose it safely.

Pharmacokinetic Overlap: The CYP3A4 Connection

Both oral micronized progesterone and trazodone are substrates of the cytochrome P450 3A4 (CYP3A4) enzyme system. This shared metabolic pathway creates the potential for competitive inhibition at the enzyme level, which could raise plasma concentrations of one or both drugs when taken together.

Progesterone undergoes extensive first-pass hepatic metabolism. The Prometrium prescribing information identifies CYP3A4 as a primary metabolic pathway, with CYP2C19 serving as a secondary route. Oral bioavailability is low (estimated at roughly 10% due to first-pass effect), and the drug produces active metabolites, including 5-alpha-pregnanolone (allopregnanolone), a potent positive allosteric modulator of the GABA-A receptor [2]. This metabolite is directly responsible for progesterone's sedative properties.

Trazodone is also metabolized primarily by CYP3A4, yielding the active metabolite meta-chlorophenylpiperazine (mCPP) [3]. When a strong CYP3A4 inhibitor such as ketoconazole is co-administered, trazodone AUC increases by approximately 34% and peak concentration rises by 36%, according to pharmacokinetic data in the trazodone FDA label. Progesterone is not a strong CYP3A4 inhibitor. In vitro data suggest it exerts weak-to-moderate inhibitory effects on CYP3A4 at supraphysiologic concentrations [4]. At standard clinical doses of 100 to 200 mg nightly, the degree of CYP3A4 inhibition is unlikely to produce the magnitude of pharmacokinetic change seen with azole antifungals.

The clinical implication: expect a modest (likely 10 to 20%) increase in trazodone exposure when adding Prometrium. This is not large enough to mandate automatic dose reduction. It is large enough to lower the threshold for side effects in patients who are sensitive to trazodone or are already near the upper end of its dose range.

Pharmacodynamic Overlap: Additive Sedation Through Different Receptors

The more clinically significant interaction is pharmacodynamic, not pharmacokinetic. Both drugs produce sedation, but they do so through distinct receptor mechanisms, and those effects stack.

Progesterone's sedative action comes from its neuroactive metabolite allopregnanolone. This metabolite enhances chloride conductance through GABA-A receptors at nanomolar concentrations, producing anxiolytic, sedative, and hypnotic effects that are pharmacologically similar to benzodiazepines [2]. A crossover study by de Lignieres et al. found that oral micronized progesterone 300 mg produced significant increases in subjective sleepiness and objective EEG changes within 2 hours of administration, with effects lasting approximately 4 to 6 hours [5].

Trazodone produces sedation through a different set of targets. At low doses (25 to 100 mg, the range commonly used for insomnia), its primary sedating mechanism is antagonism of histamine H1 receptors and serotonin 5-HT2A receptors, combined with alpha-1 adrenergic blockade [3]. At antidepressant doses (150 to 400 mg), serotonin reuptake inhibition becomes more relevant, but the sedation profile remains dominated by receptor antagonism.

Because these two drugs activate sedation through non-overlapping receptor systems (GABA-A potentiation vs. H1/5-HT2A antagonism/alpha-1 blockade), their combined effect is additive rather than synergistic. A patient taking Prometrium 200 mg at bedtime who adds trazodone 50 mg will experience more sedation than either drug alone, but not exponentially more. The risk is meaningful in three scenarios: elderly patients (age 65+), patients with baseline cognitive impairment, and patients taking additional CNS depressants such as benzodiazepines, gabapentinoids, or opioids.

Severity Rating Across Drug Interaction Databases

Different clinical decision support systems classify this interaction at varying levels. The disagreement reflects the moderate, manageable nature of the risk.

Lexicomp rates the general CNS depressant combination category as severity C ("Monitor therapy"). Micromedex classifies trazodone interactions with other sedating agents as "moderate" with "fair" documentation quality. Clinical Pharmacology flags the pair under its sedation-overlap algorithm and recommends monitoring without automatic dose changes.

No major database classifies the combination as contraindicated (severity X) or as requiring mandatory avoidance. The American College of Obstetricians and Gynecologists (ACOG) guidelines on hormone therapy do not single out trazodone as a problematic co-medication with progesterone. The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy also does not flag this specific combination [6].

Who Is Most at Risk

Not every patient taking both drugs will experience problematic sedation. Risk stratification helps clinicians decide how aggressively to monitor.

Higher-risk patients include women over age 65 (pharmacokinetic clearance of both drugs declines with age; trazodone half-life extends from 5 to 9 hours in younger adults to 7 to 13 hours in elderly patients per the FDA label), patients with hepatic impairment (both drugs depend on hepatic CYP metabolism), patients with BMI <20 (lower volume of distribution may raise peak plasma levels), and patients concurrently taking CYP3A4 inhibitors such as fluconazole, erythromycin, diltiazem, or grapefruit juice.

Lower-risk patients include women under 60 with normal hepatic function who take progesterone 100 mg (not 200 mg) and low-dose trazodone (25 to 50 mg) at bedtime. In this population, the sedation overlap may actually be clinically desirable. A 2016 retrospective chart review of 312 menopausal women at a university menopause clinic found that 23% were prescribed both a sedating antidepressant and progesterone concurrently, with only 4.2% requiring dose adjustment for excessive sedation [7].

Dose-Adjustment and Timing Strategies

The single most effective mitigation strategy is timing alignment. Both drugs should be taken at bedtime, not at different times of day, to concentrate the sedation window during sleep hours.

For a patient starting both drugs simultaneously, the recommended approach is to begin trazodone at 25 mg (half the usual starting dose) and titrate upward in 25 mg increments every 5 to 7 days based on sleep response and next-morning alertness. The progesterone dose should be set by the clinical indication: 100 mg nightly for endometrial protection in women with a uterus on combined HRT, or 200 mg nightly for 12 days per month in sequential regimens, per ACOG guidance [8].

If a patient is already stable on one drug, adding the second drug at a reduced dose with a planned 2-week reassessment is reasonable. The reassessment should include direct questions about next-morning grogginess, daytime concentration, dizziness on standing, and any falls or near-falls.

Dose reduction is indicated when a patient reports persistent daytime somnolence beyond the first 5 to 7 days of combination therapy. Trazodone is the more easily adjustable agent (25 to 50 mg decrements carry minimal risk of withdrawal or rebound insomnia at low doses). Reducing progesterone dose below the minimum effective dose for endometrial protection (100 mg continuous or 200 mg cyclic) is not advisable without gynecologic consultation, because inadequate progesterone exposure raises the risk of endometrial hyperplasia during estrogen therapy [9].

Monitoring Protocol

A structured monitoring approach reduces the chance of missing clinically significant sedation before it causes harm.

Week 1: Phone or patient-portal check-in. Ask about subjective sedation severity on a 0-to-10 scale, morning grogginess duration, and any falls, dizziness, or cognitive complaints. A sedation score above 6 or grogginess lasting past 10 a.m. warrants a dose review.

Week 2 to 4: Repeat assessment. By this point, pharmacokinetic steady state is established for both drugs (trazodone reaches steady state in 3 to 5 days; progesterone reaches steady state in approximately 6 to 8 doses during continuous use). If sedation has not resolved or adapted by week 4, a dose adjustment is needed rather than continued observation.

Ongoing: At each routine HRT follow-up (typically every 6 to 12 months), reassess the trazodone indication. Many patients initiated on low-dose trazodone for insomnia can taper off after sleep hygiene improvements or resolution of acute stressors. Removing the trazodone eliminates the interaction entirely.

Blood pressure monitoring deserves specific mention. Trazodone causes orthostatic hypotension through alpha-1 blockade. Progesterone may produce mild vasodilation through smooth muscle relaxation [10]. In combination, postural blood pressure drops may exceed those seen with either agent alone. Patients should be counseled to rise slowly from seated or supine positions, particularly during the first 2 weeks.

Alcohol and Other Potentiators

Ethanol amplifies CNS depression from both drugs. The Prometrium label explicitly warns that co-administration with alcohol increases progesterone peak plasma concentration by 54% to 100%, likely through competitive inhibition of first-pass hepatic metabolism and increased gastric absorption of the oil-filled capsule. The trazodone label similarly warns against alcohol co-use due to additive CNS depression.

Patients taking both progesterone and trazodone at bedtime should avoid alcohol within 4 hours of their evening dose. A single glass of wine at dinner (consumed 3 or more hours before dosing) is unlikely to cause clinically meaningful potentiation in most patients. Binge drinking or heavy evening alcohol use while on this combination represents a genuine safety concern for respiratory depression, aspiration risk, and fall injuries.

Other CNS depressants that compound the risk include benzodiazepines, Z-drugs (zolpidem, eszopiclone), gabapentin, pregabalin, muscle relaxants (cyclobenzaprine, tizanidine), and first-generation antihistamines (diphenhydramine, hydroxyzine). Patients on triple or quadruple CNS depressant regimens should undergo a deprescribing review with a focus on eliminating redundant sedating agents.

When to Consider Alternative Agents

For patients who cannot tolerate the sedation combination, two alternative approaches exist. The first is switching the sleep agent: melatonin 0.5 to 3 mg or ramelteon 8 mg produce sleep-promoting effects through melatonin receptor agonism without CNS depression, eliminating the pharmacodynamic overlap entirely [11]. The second is switching the progesterone formulation: vaginal micronized progesterone (Endometrin, Crinone) achieves high local endometrial concentrations with substantially lower systemic absorption and minimal allopregnanolone production, reducing or eliminating progesterone-related sedation [12]. A 2012 study published in Fertility and Sterility confirmed that vaginal progesterone produced 8-fold lower serum allopregnanolone levels compared with oral progesterone at equivalent doses [12].

Switching from oral to vaginal progesterone is not always straightforward. The Endocrine Society guideline notes that oral micronized progesterone at 200 mg for 12 days/month remains the best-studied regimen for endometrial protection in HRT, and vaginal formulations, while effective, have less long-term safety data in this specific context [6]. This decision requires shared decision-making between the prescriber and patient.

Patient Counseling Points

Patients prescribed both oral micronized progesterone and trazodone should receive these specific instructions:

Take both medications at bedtime with food. The peanut oil vehicle in Prometrium capsules requires dietary fat for optimal absorption, and bedtime dosing converts the sedation overlap into a sleep benefit rather than a daytime impairment.

Do not drive, operate machinery, or make critical decisions for at least 8 hours after taking both medications. Next-morning impairment may persist longer than expected, particularly during the first 1 to 2 weeks.

Report any of the following to your prescriber promptly: persistent grogginess past mid-morning, dizziness when standing, unexplained bruising (which may indicate falls during nocturnal bathroom trips), or confusion.

Do not stop either medication abruptly without clinician guidance. Trazodone discontinuation at higher doses may produce withdrawal-like symptoms, and stopping progesterone during estrogen therapy removes endometrial protection.

Women with peanut allergies should not take Prometrium, as the capsule contains peanut oil per the FDA label. This is unrelated to the trazodone interaction but is frequently overlooked during medication reconciliation.

Baseline liver function tests (ALT, AST) are recommended before co-initiating these agents in patients with known hepatic risk factors, given both drugs' dependence on hepatic CYP metabolism [3].